RRML - Versant HCV Genotype 2.0 Assay (LiPA) in Hepatitis C Virus Genotype Determination
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- April 2024 -
 
A comprehensive review of Prof... 24
Recomandarea comună EFLM-COLA... 14
Monocyte to high-density lipop... 10
Anti-thyroid peroxidase (TPO) ... 10
Understanding the key differen... 9
Understanding the pathogenesis... 7
Romanian Review of Laboratory ... 6
Function of the S1P pathway in... 6
Predictive value of expression... 6
Comparison of two analytical m... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 12(3)/2008
XML
TXT

Versant HCV Genotype 2.0 Assay (LiPA) in Hepatitis C Virus Genotype Determination

Elena Luminiţa Enache, Liviu S. Enache


Abstract:

Hepatitis C virus (HCV) is a major cause of chronic liver disease, the prevalence of the infection being currently estimated at approximately 170 milion persons worldwide. HCV isolates have been classified into six main genotypes. Quick and accurate genotyping of HCV is becoming increasingly important for clinical management of chronic infection and as an epidemiological marker. Genotyping methods are frequently based on the analysis of the 5’ untranslated region (5’UTR) of HCV genome, which is not appropriate for the accurate discrimination of HCV strains at a subtype level. The newly developed Versant HCV Genotype 2.0 Assay (LiPA) uses sequence information from both the 5’UTR and the core region allowing the distinction between subtypes 1a and 1b inside genotype 1 and between genotype 1 and subtypes c to l of genotype 6. Hereby, we make a review of the literature evaluating this new genotyping assay.

Keywords: hepatitis C virus,genotyping,reverse hybridization,sequencing.

 
  PDF Download full text PDF
(242 KB)
     
 
How to cite
Enache EL, Enache LS. Versant HCV Genotype 2.0 Assay (LiPA) in Hepatitis C Virus Genotype Determination. Rev Romana Med Lab. 2008;12(3):47-53